CA3234836A1 - Regime contraceptif comprenant un niveau reduit d'oestrogene - Google Patents

Regime contraceptif comprenant un niveau reduit d'oestrogene Download PDF

Info

Publication number
CA3234836A1
CA3234836A1 CA3234836A CA3234836A CA3234836A1 CA 3234836 A1 CA3234836 A1 CA 3234836A1 CA 3234836 A CA3234836 A CA 3234836A CA 3234836 A CA3234836 A CA 3234836A CA 3234836 A1 CA3234836 A1 CA 3234836A1
Authority
CA
Canada
Prior art keywords
mcg
estrogen
consecutive days
progestogen
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234836A
Other languages
English (en)
Inventor
Roger M. Boissonneault
Ryan Loughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millicent Pharma Ltd
Original Assignee
Millicent Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/483,199 external-priority patent/US20230070977A1/en
Application filed by Millicent Pharma Ltd filed Critical Millicent Pharma Ltd
Publication of CA3234836A1 publication Critical patent/CA3234836A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

L'invention concerne un régime contraceptif qui permet une réduction du niveau d'oestrogène. Le régime contraceptif peut être utilisé afin de traiter des symptômes associés à l'endométriose ou à des fibromes.
CA3234836A 2021-09-07 2022-09-07 Regime contraceptif comprenant un niveau reduit d'oestrogene Pending CA3234836A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163241178P 2021-09-07 2021-09-07
US63/241,178 2021-09-07
US17/483,199 2021-09-23
US17/483,199 US20230070977A1 (en) 2021-09-07 2021-09-23 Contraceptive regimen including reduced level of estrogen
PCT/IB2022/058420 WO2023037264A1 (fr) 2021-09-07 2022-09-07 Régime contraceptif comprenant un niveau réduit d'oestrogène

Publications (1)

Publication Number Publication Date
CA3234836A1 true CA3234836A1 (fr) 2023-03-16

Family

ID=83506501

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234836A Pending CA3234836A1 (fr) 2021-09-07 2022-09-07 Regime contraceptif comprenant un niveau reduit d'oestrogene

Country Status (2)

Country Link
CA (1) CA3234836A1 (fr)
WO (1) WO2023037264A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5888543A (en) 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US20020177580A1 (en) * 2001-05-23 2002-11-28 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
CN1878558A (zh) 2003-11-14 2006-12-13 沃纳奇尔科特公司 梯度雌激素避孕药
US8461138B2 (en) 2005-06-29 2013-06-11 Warner Chilcott Company, Llc Quadraphasis continuous graduated estrogen contraceptive
US20230135376A1 (en) * 2020-06-25 2023-05-04 Millicent Pharma Limited Multiphasic contraceptive and/or hormone replacement therapy

Also Published As

Publication number Publication date
WO2023037264A1 (fr) 2023-03-16

Similar Documents

Publication Publication Date Title
EP0354921B1 (fr) Utilisation de la mélatonine pour la fabrication d'une composition contraceptive
US5898032A (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US8450299B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Kailas et al. Contraception during perimenopause
Erkkola et al. Role of progestins in contraception
CZ288062B6 (cs) Přípravek pro ženskou antikoncepci
CA2582530A1 (fr) Procedes de traitement hormonal utilisant des schemas posologiques a cycle etendu a augmentation de dosage
NO313269B1 (no) Farmasöytisk kombinasjonspreparat for hormonell antikonsepsjon
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
AU781835B2 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
CA3234836A1 (fr) Regime contraceptif comprenant un niveau reduit d'oestrogene
US20230070977A1 (en) Contraceptive regimen including reduced level of estrogen
US20230135376A1 (en) Multiphasic contraceptive and/or hormone replacement therapy
WO1999025360A2 (fr) Regime progestatif-antiprogestatif
AU2006215818A1 (en) Contraceptive pharmaceutical preparation
Abadi et al. The role of low dosage combined oral contraceptive pill in perimenopausal women
Contraceptives Progestogen-Only Contraception
Ahrendt et al. Estrogen Free Contraception: progestin-only systems
Sedlecky et al. Management with Female Contraceptives of Issues Associated
Ahrendt et al. Reproduktionsmedizin und Endokrinologie
Narendran Hormonal Contraception in Female: Advantages and Disadvantages
Kovacs Luteal contraception
Savage Contraception During Perimenopause
Hickey Drugs for Breakthrough Bleeding Due to Hormonal Therapies
Sedlecky et al. Management of Issues Associated with Female Contraceptives